Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib with Idarubicin and Cytarabine in AML and MDS
NCT00096122Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2004
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tipifarnib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by National Cancer Institute. Primary endpoints: Number of Participants With Complete Response at 21 days and Maximum Tolerated Dose (MTD) at 21 days. Started Sep 2004; status: completed.
02
Drugs
tipifarnib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00096122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00096122.